Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and/or Trametinib in Relapsed/Refractory Multiple Myeloma
NCT03091257Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2017
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dabrafenib + trametinib and trametinib in multiple myeloma (MM) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Overall Response Rate at 100 weeks. Started Jun 2017; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03091257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03091257.